TP73-AS1在肿瘤中的表达及调控作用

Expression and regulatory effect of P73 antisense RNA 1T in tumors

随着高通量测序技术的发展,成千上万种长链非编码RNA(long non-coding RNA,lncRNA)进入人们的视野。lncRNA是一类长度超过200个核苷酸并缺少开放阅读框的不具备蛋白质编码功能的RNA [1-2]。研究发现lncRNA参与诸多生物学进程的关键步骤,包括染色质重塑、基因转录、转录后调节和蛋白质翻译等[3-5]。LncRNA机制的不断被阐明,也为肿瘤的研究提供了新的可能。LncRNA在多种肿瘤的增殖、迁移侵袭和抗凋亡等生物学特性中发挥重要作用,可通过转录、表观遗传调节、印迹、剪接和亚细胞转运等参与肿瘤的发生发展。为让患者获得更好的治疗效果,研究者们长期致力于寻找各种有效的肿瘤标记物,其中lncRNA在恶性肿瘤诊断和治疗中就具有重要的潜在应用价值[6]。

The discovery of abundant new long non-coding RNAs(lncRNAs) and extensive investigation of their roles in various diseases have been reported, especially in cancers. The lncRNA P73 antisense RNA1T(TP73-AS1) is involved in dysregulation of cell signaling and closely correlated with cancer development, progression, and response to therapy. This review is a brief update of the current knowledge related to the role of TP73-AS1 in cancer-associated molecular pathways and pathophysiology, and possible determinants for TP73-AS1 to function as a biomarker, aiming to stimulate the basic investigation of TP73-AS1 as well as its translation to clinical applications.